Pharmacy Prior Authorization

AETNA BETTER HEALTH ILLINOIS FAMILY HEALTH PLAN (MEDICAID)

Cialis for BPH (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-844-242-0908**.

When conditions are met, we will authorize the coverage of Cialis for BPH (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug	Name (please circle)				
Cialis 2.5mg (tadalafil)		Cialis 5mg (tadalafil) Ci	Cialis 10mg, 20mg (tadalafil)		
Other	, please specify				
Quantity Route of Administration		Frequency St	rength		
		Expected Length of therapy			
	ent Information nt Name:				
Patier	nt ID·				
Patier	nt Phone:				
Pres	cribing Physician				
Physi	cian Name:				
Specialty:		NPI Number:			
Physician Fax:		Physician Phone:			
Physician Address:		City, State, Zip:			
Diagnosis:		ICD Code:			
Please	e circle the appropriate answe	er for each question.			
1.		authorized this medication in the past for this horization is on file under this plan)?	Υ	N	
	[If no, then skip to questi	on 3.]			
2.		rovement in symptoms (i.e., International e (I-PSS) or AUA symptom score)?	Υ	N	
	[No further questions.]				
3.	Is this request for daily u	se of Cialis 2.5mg or 5mg tablets?	Υ	N	
	[If no, then no further que	estions.]			

Reference Number: C4387-C / Effective Date: 08/23/2017

Prescriber (Or Authorized) Signature		Date				
affirm that the information given on this form is true and accurate as of this date.						
Со	mments:					
	Is the patient using any nitrate therapy (e.g., nitroglycerin, isosorbide dinitrate, isosorbide mononitrate or amyl nitrate) or Adempas?		Y	N		
	[If no, then no further questions.]					
6.	Has the patient experienced an inadequate treatment response, intolerance, or contraindication to finasteride (for at least 6 months)?		Υ	N		
	[If no, then no further questions.]					
	Please list names of agents tried:	_				
5.	Has the patient experienced an inadequate treatment response, intolerance, or contraindication to alfuzosin or tamsulosin and one additional formulary alpha blocker agent (e.g., doxazosin, terazosin)?		Υ	N		
	[If no, then no further questions.]					
4.	Does the patient have a diagnosis of benign prostatic hypertrophy (BPH)?		Υ	N		

Reference Number: C4387-C / Effective Date: 08/23/2017